Newsflash:
- Many Drug Labels Missing Dose, Safety Info for Kids
- Lilly Oncology to Highlight Final Results for Phase III Study in Most Common Form of Lung Cancer
- J&J Opens Doxil Rationing Program to New Patients
- FDA Issues Safety Label Changes for Fingolimod
- FDA Backs Pill to Block HIV Infection
- FDA Advisers Recommend Approving Arena Weight-Loss Drug
UK's NICE Turns Down Cancer Drugs From Merck, Roche, Amgen
Fox Business (01/24/12)
The U.K.'s National Institute for Health and Clinical Excellence recently rejected three drugs from Merck, Roche, and Amgen. The drugs, Erbitux, Astavin, and Vecitibix, respectively, are designed to treat metastasized colorectal cancer, or cancer that has spread to other areas of the body. The ruling was made as it was not felt that the drugs offered enough value for the money to be worked into the publicly funded National Health Service.
Abstract News © Copyright 2011
INFORMATION, INC.
Sponsor Highlights
Our Sponsors:
Sitemap
© Pharmacist e-Link
